Navigation Links
New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
Date:5/20/2008

A Separate Retrospective Analysis of US Employer Claims Suggests a Benefit of Anti-Tumor Necrosis Factor Therapies on Absenteeism Among Employees with

Inflammatory Bowel Disease

SAN DIEGO, May 20 /PRNewswire/ -- Data from a new analysis of the Active Ulcerative Colitis Trials (ACT 1 and ACT 2) showed that at week 8, more than 60 percent of patients with moderately to severely active ulcerative colitis (UC) receiving REMICADE(R) (infliximab) achieved clinical response regardless of disease duration (less than three years versus at least three years). Investigators also reported that at week 30, significant improvements were maintained with nearly half of REMICADE-treated patients having a clinical response. Significant improvements in disease remission and mucosal healing were also reported at weeks 8 and 30 among patients receiving REMICADE and meeting the disease duration criteria. These findings were presented today at the annual Digestive Disease Week(R) (DDW) meeting.

"These data are encouraging because we see that REMICADE is an effective treatment option for patients with active ulcerative colitis, whether recently diagnosed or struggling with the condition for many years," said Dr. Bruce Sands, Associate Professor of Medicine at Harvard Medical School, and study investigator. "Regardless of disease duration, patients receiving REMICADE showed significant improvements in clinical response, remission and mucosal healing, all goals of therapy in the treatment of ulcerative colitis."

In the analysis of 728 patients from ACT 1 and ACT 2, 254 patients had UC for less than three years and 474 patients had UC for at least three years. Clinical response, clinical remission and mucosal healing rates at week 8 for the combined REMICADE treatment group (5 mg/kg and 10 mg/kg) were all significantly higher than the placebo group (P < 0.01) regardless of disease duration; clinical response: 62 percent versus 33 percent for
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014  PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... Award for Vision, Innovation, and Leadership has been awarded to ... award recognizes an individual who has had a significant impact ... for several decades. "I am honored to ... Peltz , Ph.D., CEO of PTC Therapeutics, Inc. "When I ...
(Date:11/21/2014)... -- Market research firm Kalorama information says that 2014 will ... the medical device industry.  The firm thinks the $360 ... 3% growth this year, which led firms to look ... and entrance by acquisition into new competitive zones.  The ... The Global Market for Medical Devices, 5 th ...
(Date:11/21/2014)... AUSTIN, Texas , 21. November 2014 ... das, was sich am Morgen des 14. Februar 2014 ... Valentinstag jedoch wohl kaum vergessen. Video - ... gesagt, dass ich dabei war, mein morgendliches Training zu ... ich waren zu der Zeit begeisterte Anhänger ...
Breaking Medicine Technology:PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3Kalorama: 2014 The "Year of The Buy" in Medical Device Industry 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3
... AccuVein LLC today announced it had signed an exclusive distribution ... vein finder in India . With this new agreement ... , , ... blood draw , IV infusion and blood donation by projecting ...
... May 18 Teva Women ,s Health, Inc. ... or low dose of ENJUVIA® (synthetic conjugated estrogens, B) tablets ... at night by hot flashes compared to patients treated with ... Clinical Meeting of the American College of Obstetricians and Gynecologists ...
Cached Medicine Technology:AccuVein Signs Exclusive Distribution Agreement in India to Sell Vein Illumination Device 2AccuVein Signs Exclusive Distribution Agreement in India to Sell Vein Illumination Device 3New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 2New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 3New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 4New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 5New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 6New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 7
(Date:11/22/2014)... 21, 2014 (HealthDay News) -- A clinical trial of ... been halted a year early because the results show ... the disease and reduce the risk of stroke. ... 25 medical centers in the United States and Canada, ... Lung, and Blood Institute (NHLBI). Researchers compared monthly ...
(Date:11/22/2014)... -- The widely used heart drug digoxin is associated ... who have the heart rhythm disorder atrial fibrillation but ... Atrial fibrillation is a common form of irregular ... risk for stroke among older Americans. Digoxin has been ... irregular heartbeat, the authors of the new study said, ...
(Date:11/21/2014)... 21, 2014 Body Well Therapy, a leading ... accepts Spafinder massage gift cards and gift ... massage in all service areas including throughout Florida and the ... go to the spa at all to redeem your Spafinder ... Body Well. "We may not be able to transport all ...
(Date:11/21/2014)... 21, 2014 (HealthDay News) -- Scientists say they,ve mapped the ... from a British man,s brain, in hopes it might help ... 21 in the journal Genome Biology , the tapeworm ... of Chinese ethnicity. "This infection is so rare worldwide ... not diagnosed ... until the worm was pulled out from ...
(Date:11/21/2014)... 21, 2014 Saint Luke’s Mid ... The Guidelines®–Heart Failure Gold-Plus Quality Achievement Award for ... American Heart Association/American College of Cardiology Foundation in ... , Get With The Guidelines–Heart Failure is a ... the most up-to-date, research-based guidelines with the goal ...
Breaking Medicine News(10 mins):Health News:Sickle Cell Anemia Treatment So Successful in Kids That Trial Is Halted 2Health News:Treating Irregular Heartbeat With Digoxin May Come With Risks 2Health News:Treating Irregular Heartbeat With Digoxin May Come With Risks 3Health News:Body Well Mobile Massage Announces Acceptance of Spafinder Gift Cards for In Home Massage, Hotel Massage for Travelers 2Health News:Ick! Tapeworm Infecting Man's Brain Yields Genetic Secrets 2Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 2Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 3Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 4
... (HealthDay News) -- Children who are allergic to penicillin ... additional drug allergies, new research suggests. Pediatric patients ... authors noted. Prior research in adults has suggested that ... allergies to other medications. But in the new ...
... one Michigan State University professor will explore why in old ... whites. Prior research also shows of those 71 years ... mild cognitive impairment, or various types of mental processing problems, ... first to produce statistics about life expectancy with and without ...
... new study conducted by Boston University School of Medicine (BUSM) ... believe that chewing the plant khat is harmful to one,s ... The study, which is published online in the journal ... 2013 students Paul Yi, John Kim and Khalil Hussein. Richard ...
... warned that, in addition to causing obesity, eating too ... risk for colon cancer. Now, researchers at Temple University ... The findings, "Epigenetic Differences in Normal Colon Mucosa of ... in the March issue of the American Association for ...
... HIV-positive patient, one of her first questions is whether he ... response is about dead relatives or friends. "We talk about ... experience will be very different," said the infectious-disease specialist at ... "Yes it,s the same virus and could have the same ...
... - Researchers from Boston University School of Medicine (BUSM) ... with breast pain who receive imaging (mammograms, MRIs or ... diagnostic testing, but do not gain benefit from these ... Journal of General Internal Medicine. Breast pain ...
Cached Medicine News:Health News:Kids' Penicillin Allergy May Not Signal Other Drug Reactions 2Health News:New research will shed light on racial gap in dementia 2Health News:BUSM student-published study focuses on khat chewing in Yemeni culture 2Health News:Study shows how high-fat diets increase colon cancer risk 2Health News:Federal grant enables HIV testing, treatment in the Augusta area 2Health News:Federal grant enables HIV testing, treatment in the Augusta area 3Health News:Research finds little benefit of breast imaging tests for women with breast pain 2
For the quantitative determination of Inorganic Phosphorus in serum. Linearity: 12.0 mg/dl....
Amylase (EPS-G7, kinetics), Wavelength: 405 nm. Linear range; 5-1500 IU/L....
For the kinetic quantitative determination of g-Glutamyl Transferase in serum for manual and/or automated procedures....
Intended for the quantitative determination of alphaamylase activity in serum. Single vial, dry powder reagent. Reaction: Kinetic. Wavelength: 405 nm. Linearity: 2000 U/L at 37C....
Medicine Products: